OpenAI, US FDA Discuss AI Integration in Drug Evaluation

OpenAI has held multiple meetings with the U.S. Food and Drug Administration to explore the use of artificial intelligence in drug evaluation, according to a report by Wired.

The discussions reportedly involved a small team from OpenAI and two associates from Elon Musk’s Department of Government Efficiency.

The meetings have taken place over recent weeks, sources familiar with the matter told Wired.

The talks signal growing interest in applying AI to streamline regulatory processes in the healthcare sector.

---

• OpenAI met with the U.S. FDA to discuss AI use in drug evaluation

• Meetings included associates from Elon Musk’s Department of Government Efficiency

• Discussions occurred multiple times in recent weeks

Source: REUTERS